ribA

Abstract: The invention provides ribA polypeptides and polynucleotides encoding ribA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribA polypeptides to screen for antibacterial compounds.

Description: ribA RELATED APPLICATIONS This application claims benefit of US Patent Application Number filed November 25. 1997 FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and polypeptides. and their production and uses, as well as their vaπants. agonists and antagonists, and their uses In particular, the mvention relates to novel polynucleotides and polypeptides of the GTP cyclohydrolase II family, hereinafter referred to as "ribA" BACKGROUND OF THE INVENTION It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics The Staphylococci make up a medically important genera of microbes They are known to produce two types of disease, invasive and toxigemc Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues Staphylococcus aureus is the second leading cause of bacteremia in cancer patients Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common There are at least three clinical conditions resulting from the toxigemc properties of Staphylococci The manifestation of these diseases result from the actions of exotoxins as opposed to tissue invasion and bacteremia These conditions include Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome Riboflavm (vitamin B2) is a member of the B complex of vitamins which function as coenzymes m metabolic reactions Riboflavm has two coenzyme forms, flavin mononucleotide (FMN) and flavm adenme dinucleotide (FAD) which act in oxidation-reduction reactions such as the cytochrome system of electron transport and the oxidative degradation of pyruvate. fatty acids and ammo acids The first committed step in the biosynthesis of riboflavm is the opemng of the lmidazole ring of GTP In the presence of 3 H2O and Mg ++ , the C-8 of GTP is released as formate accompanied by the release of pyrophosphate by the action of GTP cyclohyrolase II (GCH2. EC 3 5 4 25) This enzyme function is encoded by ribA m bacteria and ribl m yeast species Through a series of steps, involving 3,4-dιhydroxy-2-butanone 4 phosphate synthase {ribA). 6.7-dιmethyl-8-πbιtyllumazme synthase {nbH), riboflavm synthase {ribB). pyrrmidme dearrunase and pyπmidme reductase {rtbG). enzymes encoded by genes within the riboflavm biosynthesis operon, riboflavm is formed Because GCH2 catalyzes the first committed step in the biosynthesis of riboflavm (Richter G. et al (1993) Biosynthesis of riboflavm cloning, sequencmg. mapping, and expression of the gene coding for GTP cyclohydrolase II in Eschenchia coh J Bacteπol 175 4045-4051), is present in many pathogenic microorganisms, and since riboflavm biosynthesis has shown to be required for virulence m the swme pathogen Actinobacillus pleuropneumomae (Fuller, TE, et al (1996) A riboflavm auxotroph of Actinobacillus pleuropneumomae is attenuated m swme Infect Immun 64 4659-4664). it represents a broad spectrum antibacteπal as well as antifungal target The frequency of Staphylococcus aureus infections has πsen dramatically m the past few decades This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics This phenomenon has created a demand for both new anti-microbial agents, vaccines, and diagnostic tests for this organism Clearly, there exists a need for factors, such as the ribA embodiments of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent ameliorate or correct such infection, dysfunction and disease Certain of the polypeptides of the invention possess amino acid sequence homology to a known Bacillus amylohquefaciens protein (Swiss Prot Accession no P51695. GenBank Accession no U27202, Perkms, J B et al . In Bacillus subtihs and Other Gram-Positive Bacteria Eds Sonenshem, A L et al . 1993 American Society for Microbiology ) SUMMARY OF THE INVENTION It is an object of the mvention to provide polypeptides that have been identified as novel πbA polypeptides by homology between the ammo acid sequence set out in Table 1 [SEQ ID NO 2 or 4] and a known ammo acid sequence or sequences of other proteins such as Bacillus amyloliquefaciens protein It is a further object of the mvention to provide polynucleotides that encode πbA polypeptides, particularly polynucleotides that encode the polypeptide herein designated πbA In a particularly prefeπed embodiment of the mvention, the polynucleotide compπses a region encoding πbA polypeptides compπsmg a sequence set out m Table 1 [SEQ ID NO 1, 3 or 7] which includes a full length gene, or a vaπant thereof In another particularly preferred embodiment of the invention, there is a novel πbA protein from Staphylococcus aureus compπsmg the ammo acid sequence of Table 1 [SEQ ID NO 2 or 4], or a variant thereof As a further aspect of the mvention, there are provided isolated nucleic acid molecules encoding nbA, particularly Staphylococcus aureus πbA, including mRNAs. cDNAs, genomic DNAs Further embodiments of the mvention mclude biologically, diagnostically, prophylactically, clinically or therapeutically useful vaπants thereof, and compositions compπsmg the same In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophvlactic purposes, m particular genetic immunization Among the particularly prefeπed embodiments of the mvention are naturally occurring allelic vaπants of πbA and polypeptides encoded thereby As another aspect of the mvention, there are provided novel polypeptides of Staphylococcus aureus referred to herem as πbA as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful vaπants thereof, and compositions compπsmg the same Among the particularly preferred embodiments of the mvention are vaπants of πbA polypeptide encoded by naturally occurring alleles of the πbA gene In a prefeπed embodiment of the mvention, there are provided methods for producing the aforementioned nbA polypeptides In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides. useful as antibacteπal agents, including, for example, antibodies In accordance with certain prefeπed embodiments of the mvention, there are provided products, compositions and methods for assessing nbA expression- treating disease, assaying genetic vaπation, and administering a πbA polypeptide or polynucleotide to an organism to raise an rmmunological response against a bactena, especially a Staphylococcus aureus bactena In accordance with certain prefeπed embodiments of this and other aspects of the mvention, there are provided polynucleotides that hybπdize to nbA polynucleotide sequences, particularly under stringent conditions In certain prefeπed embodiments of the mvention, there are provided antibodies against πbA polypeptides In other embodiments of the mvention, there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the mvention compπsmg contactmg a polypeptide or polynucleotide of the mvention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction bemg associated with a second component capable of providing a detectable signal m response to the binding or interaction of the polypeptide or polynucleotide with the compound, and determinmg whether the compound bmds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polvnucleotide In accordance with yet another aspect of the mvention. there are provided nbA agonists and antagonists, preferably bactenostatic or bactenocidal agonists and antagonists In a further aspect of the mvention. there are provided compositions compnsmg a πbA polynucleotide or a πbA polypeptide for administration to a cell or to a multicellular organism Vanous changes and modifications within the spiπt and scope of the disclosed mvention will become readily apparent to those skilled m the art from reading the following descπptions and from reading the other parts of the present disclosure DESCRIPTION OF THE INVENTION The mvention relates to novel πbA polypeptides and polynucleotides as descπbed in greater detail below In particular, the mvention relates to polypeptides and polynucleotides of a novel nbA of Staphylococcus aureus. which is related by ammo acid sequence homology to Bacillus amyloliquefaciens polypeptide. The invention relates especially to ribA having the nucleotide and amino acid sequences set out in Table 1 as SEQ ID NO: 1 and SEQ ID NO: 2 respectively. TABLE 1 ribA Polynucleotide and Polypeptide Sequences (A) Sequences from Staphylococcus aureus ribA polynucleotide sequence [SEQ ID NO: 1]. 5 ' - ATGCAATTCGATAATATTGACAGTGCTTTAATGGCTTTAAAAAATGGAGAAACAATTATTGTAGTAGAT GATGAGAATCG TGAAAATGAAGGTGATTTAGTAGCGGTTACTGAATGGATGAACGATAATACCATTAATTTTATGGCGAA AGAAGCAAGGG GATTAATATGCGCACCAGTGTCTAAAGATATTGCACAACGTTTGGATTTGGTACAAATGGTTGATGATA AC CCGACATC TTTGGTACGCAATTTACAGTGAGTATTGATCATGTAGATACAACAACAGGAATTAGTGCTTATGAACGT ACATTGACTGC CAAAAAGCTCATTGATCCTAGTAGTGAAGCTAAAGATTTTAATCGTCCTGGTCATTTATTTCCATTAGT AGCACAAGATA AAGGCGTATTAGCTAGAAATGGACACACAGAAGCGGCTGTTGATTTAGCTAAACTTACTGGTGCCAAGC CCGCTGGTGTC ATTTGTGAGATTATGAATGATGACGGCACGATGGCGAAAGGACAAGATTTACAAAATTTTAAAGAAAAA CATCAATTAAA GATGATTACGATTGATGATTTAATTGAATATCGTAAAAAATTAGAACCAGAAATTGAATTTAAGGCAAA AGTGAAAATGC CTACAGATTTCGGAACATTTGATATGTATGGTTTTAAAGCGACATACACAGATGAAGAGATAGTTGTAC TGACAAAAGGT GCAATTCGACAACATGAAAATGTACGCTTACATTCTGCGTGCCTTACAGGCGATATTTTCCATAGTCAA CGTTGTGATTG TGGTGCTCAACTTGAATCGTCTATGAAGTATATCAATGAACATGGTGGCATGATTATTTATCTACCTCA AGAAGGTCGTG GCATAGGATTGTTAAACAAATTACGCGCATATGAATTAATTGAGCAAGGATATGATACAGTAACTGCAA ATTTAGCATTA GGTTTTGATGAAGATTTACGAGATTATCATATTGCTGCACAGATTTTAAAATATTTTAACATCGAACAT ATCAATTTATT AAGTAATAATCCAAGTAAATTTGAGGGATTAAAACAATATGGCATTGATATTGCAGAAAGAATTGAAGT TATCGTACCAG AAACGGTACATAATCATGATTATATGGTAACGAAAAAAATAAAAATGGGTCATTTAATATAG-3 ' (B) Staphylococcus aureus nbA polypeptide sequence deduced from the polynucleotide sequence m this table [SEQ ID NO 2] NH 2 - MQFDNIDSALMALKNGETIIλΛDDENRENEGDLVAλTTEWMNDNTINFMAKEARGLICAPVSKDIAQRLD LVQMVDDNSDI FGTQFTVSIDHVDTTTGISAYERTLTAKKLIDPSSEAKDFNRPGHLFPLVAQDKGVLARNGHTEAAVDL AKLTGAKPAGV ICEIMNDDGTMAKGQDLQNFKEKHQLKMITIDDLIEYRKKLEPEIEFKAfVKMPTDFGTFDMYGFKATY TDEEIWLTKG AIRQHENVRLHSACLTGDIFHSQRCDCGAQLESSMKYINEHGGMIIYLPQEGRGIGLLNKLRAYELIEQ GYDTVTANLAL GFDEDLRDYHIAAQILKYFNIEHINLLSNNPSKFEGLKQYGIDIAERIEVIVPETλHNHDYMVTKKIKM GHLI-COOH (C) Polynucleotide sequences compnsmg Staphylococcus aureus nbA ORF sequence [SEQ ID NO 3] 5 ' - AGCCGCTGGTGTCAATTTGTGAGATTATGAATGATGACGGCACCGATGGCGAAAGGACCAAGATTTACC AAAATTTTTAAAAGAAAAACATCAATTAAAGATGATTACGATTGATGATTTAATTGAATATCGTAAAAA ATTAGAACCAGAAATTGAATTTAAGCCCAAAAGTGAAAATGCCTACAGATTTCGGAACATTTGATATGT ATGGTTTTAAAGCGACATACACAGATGAAGAGATAGTTGTACTGACAAAAGGTGCAATTCGACAACATG AAAATGTACGCTTACATTCTGCGTGCCTTACAGGCGATATTTTCCATAGTCAACGTTGTGATTGTGGTG CTCAACTTGAATCGTCTATGAAGTATATCAATGAACATGGTGGCATGATTATTTATCTACCTCAAGAAG GTCGTGGCATAGGATTGTTAAACAAATTACGCTCGTGCCACGAGGAT -3 ' (D) Staphylococcus aureus nbA polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO 4] NH 2 - RHR RKDQDLPKFLKEKHQLKMITI DDLI EYRKKLEPEIEFKPKSENAYRFRNI-COOH Deposited materials A deposit containing a Staphylococcus aureus WCUH 29 strain has been deposited with the National Collections of Industnal and Manne Bactena Ltd (herem "NCIMB"), 23 St Machar Dnve, Aberdeen AB2 1RY, Scotland on 11 September 1995 and assigned NCIMB Deposit No 40771, and refeπed to as Staphylococcus aureus WCUH29 on deposit The Staphylococcus aureus stram deposit is refeπed to herem as "the deposited stram" or as "the DNA of the deposited stram " The deposited stram contains the full length πbA gene The sequence of the polynucleotides contamed in the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling m the event of any conflict with any descnption of sequences herem The deposit of the deposited stram has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The stram will be lπevocably and without restnction or condition released to the public upon the issuance of a patent The deposited stram is provided merely as convenience to those of skill m the art and is not an admission that a deposit is required for enablement, such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited stram. and compounds deπved therefrom- and no such license is hereby granted One aspect of the mvention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus WCUH 29 stram contamed in the deposited stram Further provided by the mvention are πbA nucleotide sequences of the DNA m the deposited stram and ammo acid sequences encoded thereby Also provided by the mvention are nbA polypeptide sequences isolated from the deposited stram and ammo acid sequences deπved therefrom Polypeptides The polypeptides of the mvention mclude a polypeptide of Table 1 [SEQ ID NO 2 or 4] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of nbA. and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NO 1, 3 or 7] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and more preferably at least 90% srmilanty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and still more preferably at least 95% similaπty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and also mclude portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes polypeptides of the formula X-(Rι) m -(R 2 )-(R 3 )nN wherein, at the ammo terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R j and R3 are any ammo acid residue, m is an mteger between 1 and 1000 or zero, n is an integer between 1 and 1000 or zero, and R 2 is an ammo acid sequence of the mvention, particularly an ammo acid sequence selected from Table 1 In the formula above R is oπented so that its ammo terminal residue is at the left, bound to Rj and its carboxy terminal residue is at the πght, bound to R3 Any stretch of ammo acid residues denoted by either R group, where m and/or n is greater than 1. may be either a heteropolymer or a homopolymer, preferably a heteropolymer A fragment is a vanant polypeptide having an ammo acid sequence that entirely is the same as part but not all of the ammo acid sequence of the aforementioned polypeptides As with nbA polypeptides fragments may be "free-standmg," or compnsed within a larger polypeptide of which they form a part or region, most preferably as a single contmuous region, a smgle larger polypeptide Prefeπed fragments mclude. for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NO 2 or 4], or of vaπants thereof, such as a continuous seπes of residues that includes the ammo terminus, or a contmuous senes of residues that includes the carboxyl terminus Degradation forms of the polypeptides of the mvention m a host cell, particularly a Staphylococcus aureus, are also prefeπed Further preferred are fragments characterized by structural or functional attributes such as fragments that compπse alpha-hehx and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-formmg regions, substrate bmdmg region, and high antigenic mdex regions Also prefeπed are biologically active fragments which are those fragments that mediate activities of nbA. including those with a similar activity or an improved activity, or with a decreased undesirable activity Also included are those fragments that are antigenic or lmmunogenic m an animal, especially m a human Particularly prefeπed are fragments compπsmg receptors or domains of enzymes that confer a function essential for viability of Staphylococcus aureus or the ability to initiate, or maintain cause disease in an individual, particularly a human Vaπants that are fragments of the polypeptides of the mvention may be employed for producmg the coπesponding full-length polypeptide by peptide synthesis, therefore, these vaπants may be employed as intermediates for producmg the full-length polypeptides of the mvention In addition to the standard smgle and triple letter representations for ammo acids, the term "X" or "Xaa" may also be used m descnbmg certain polypeptides of the invention "X" and "Xaa" mean that any of the twenty naturally occunng ammo acids may appear at such a designated position m the polypeptide sequence Polynucleotides Another aspect of the mvention relates to isolated polynucleotides, including the full length gene, that encode the nbA polypeptide having a deduced ammo acid sequence of Table 1 [SEQ ID NO 2 or 4] and polynucleotides closely related thereto and vanants thereof Usmg the information provided herein, such as a polynucleotide sequence set out in Table 1 [SEQ ID NO 1, 3 or 7], a polynucleotide of the mvention encoding πbA polypeptide may be obtained usmg standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bactena usmg Staphylococcus aureus WCUH 29 cells as starting matenal. followed by obtaining a full length clone For example, to obtain a polynucleotide sequence of the invention, such as a sequence given in Table 1 [SEQ ID NO 1, 3 or 7], typically a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 m E coh or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence Clones carrymg DNA identical to that of the probe can then be distinguished using stringent conditions By sequencing the individual clones thus identified with sequencmg primers designed from the oπgmal sequence it is then possible to extend the sequence m both directions to determine the full gene sequence Conveniently, such sequencmg is performed using denatured double stranded DNA prepared from a plasmid clone Suitable techmques are described by Maniatis, T , Fritsch. E F and Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL. 2nd Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor. New York (1989) (see m particular Screening By Hybridization 1 90 and Sequencmg Denatured Double-Stranded DNA Templates 13 70) Illustrative of the mvention, the polynucleotide set out m Table 1 [SEQ ID NO 1. 3 or 7] was discovered in a DNA library denved from Staphylococcus aureus WCUH 29 The DNA sequence set out m Table 1 [SEQ ID NO 1. 3 or 7] contains an open reading frame encoding a protein having about the number of ammo acid residues set forth m Table 1 [SEQ ID NO 2 or 4] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known in the art The polynucleotide of SEQ ID NO 1, between nucleotide number 1 and the stop codon which begins at nucleotide number 1180 of SEQ ID NO 1, encodes the polypeptide of SEQ ID NO 2 The πbA polypeptide of the mvention is structurally related to other proteins of the GTP cyclohydrolase II family The mvention provides a polynucleotide sequence identical over its entire length to a coding sequence in Table 1 [SEQ ID NO 1- 3 or 7] Also provided by the mvention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment m reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcπbed. non-translated sequences, termination signals, nbosome bmdmg sites, sequences that stabilize mRNN mtrons, polyadenylation signals, and additional coding sequence which encode additional ammo acids For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded In certain embodiments of the mvention. the marker sequence is a hexa-histidine peptide. as provided in the pQE vector (Qiagen, Inc ) and descnbed m Gentz et al . Proc Natl Acad Sci USA 86 821-824 (1989), or an HA tag (Wilson etα/ , Cell 37 767 (1984) Polynucleotides of the mvention also mclude, but are not limited to. polynucleotides compπsmg a structural gene and its naturally associated sequences that control gene expression A prefeπed embodiment of the mvention is a polynucleotide of compπsmg nucleotide 1 to the nucleotide immediately upstream of or including nucleotide 1180 set forth in SEQ ID NO 1 of Table 1 , both of which encode the nbA polypeptide The mvention also mcludes polynucleotides of the formula X-(Rι ) m -(R 2 )-(R 3 ) n -Y wherein, at the 5' end of the molecule. X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal. Ri and R3 is any nucleic acid residue, m is an mteger between 1 and 3000 or zero . n is an mteger between 1 and 3000 or zero, and R 2 is a nucleic acid sequence of the mvention, particularly a nucleic acid sequence selected from Table 1 In the polynucleotide formula above R 2 is oπented so that its 5' end residue is at the left, bound to K\ and its 3' end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer In a prefeπed embodiment m and/or n is an integer between 1 and 1000. It is most prefeπed that the polynucleotides of the inventions are denved from Staphylococcus aureus. however, they may preferably be obtained from organisms of the same taxonomic genus They may also be obtained, for example, from orgamsims of the same taxonomic family or order The term "polynucleotide encodmg a polypeptide" as used herem encompasses polynucleotides that mclude a sequence encodmg a polypeptide of the mvention, particularly a bactenal polypeptide and more particularly a polypeptide of the Staphylococcus aureus nbA hav g an ammo acid sequence set out in Table 1 [SEQ ID NO 2 or 4] The term also encompasses polynucleotides that mclude a smgle contmuous region or discontinuous regions encodmg the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain codmg and/or non-coding sequences The mvention further relates to vaπants of the polynucleotides descnbed herem that encode for vaπants of the polypeptide havmg a deduced ammo acid sequence of Table 1 [SEQ ID NO 2 or 4] Vaπants that are fragments of the polynucleotides of the mvention may be used to synthesize full- length polynucleotides of the mvention Further particularly prefeπed embodiments are polynucleotides encodmg nbA vanants. that have the ammo acid sequence of nbA polypeptide of Table 1 [SEQ ID NO 2 or 4] m which several, a few, 5 to 10, 1 to 5, 1 to 3, 2. 1 or no ammo acid residues are substituted, deleted or added, in any combination Especially prefeπed among these are silent substitutions, additions and deletions, that do not alter the properties and activities of πbA Further prefeπed embodiments of the mvention are polynucleotides that are at least 70% identical over then- entire length to a polynucleotide encodmg nbA polypeptide havmg an ammo acid sequence set out m Table 1 [SEQ ID NO 2 or 4]. and polynucleotides that are complementary to such polynucleotides Alternatively, most highly prefeπed are polynucleotides that compπse a region that is at least 80% identical over its entire length to a polynucleotide encodmg πbA polypeptide and polynucleotides complementary thereto In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly prefeπed. and among these particularly prefeπed polynucleotides, those with at least 95% are especially prefeπed Furthermore, those with at least 97% are highly prefeπed among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly prefeπed, with at least 99% bemg the more prefeπed Prefeπed embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of Table 1 [SEQ ED NO 1, 3 or 7] The mvention further relates to polynucleotides that hybndize to the herem above-descnbed sequences In this regard, the mvention especially relates to polynucleotides that hybndize under stringent conditions to the herem above-descnbed polynucleotides As herem used, the terms "strmgent conditions" and "strmgent hybndization conditions" mean hybndization will occur only if there is at least 95% and preferably at least 97% identity between the sequences An example of strmgent hybridization conditions is overnight incubation at 42°C m a solution compnsmg 50%) formanude, 5x SSC (150mM NaCl, 15mM tπsodium citrate). 50 mM sodium phosphate (pH7 6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support m 0 lx SSC at about 65 °C Hybridization and wash conditions are well known and exemplified m Sambrook, et al . Molecular Cloning A Laboratory Manual. Second Edition. Cold Spring Harbor, N Y , (1989). particularly Chapter 11 therem The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth m SEQ ID NO 1 under strmgent hybndization conditions with a probe havmg the sequence of said polynucleotide sequence set forth in SEQ ID NO 1 or a fragment thereof, and isolating said DNA sequence Fragments useful for obtaining such a polynucleotide mclude, for example, probes and primers described elsewhere herem As discussed additionally herem regarding polynucleotide assays of the mvention. for instance, polynucleotides of the mvention as discussed above, may be used as a hybndization probe for RN A. cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encodmg πbA and to isolate cDNA and genomic clones of other genes that have a high sequence similaπty to the nbA gene Such probes generally will compnse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases Particularly prefeπed probes will have at least 30 bases and will have 50 bases or less For example, the codmg region of the πbA gene may be isolated by screening usmg a DNA sequence provided m Table 1 [SEQ ID NO 1, 3 or 7] to synthesize an oligonucleotide probe A labeled oligonucleotide havmg a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybndizes to The polynucleotides and polypeptides of the mvention may be employed, for example, as research reagents and matenals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herem relatmg to polynucleotide assays Polynucleotides of the mvention that are oligonucleotides denved from the sequences of Table 1 [SEQ ID NOS 1 or 2 or 3 or 4] may be used m the processes herem as descnbed. but preferably for PCR, to determine whether or not the polynucleotides identified herem m whole or in part are transcnbed in bactena m infected tissue It is recognized that such sequences will also have utility m diagnosis of the stage of mfection and type of infection the pathogen has attained The mvention also provides polynucleotides that may encode a polypeptide that is the mature protem plus additional ammo or carboxyl-terminal ammo acids, or ammo acids rntenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance) Such sequences may play a role in process g of a protem from precursor to a mature form, may allow protem transport, may lengthen or shorten protem half-life or may facilitate manipulation of a protem for assay or production, among other thmgs As generally is the case in vivo, the additional ammo acids may be processed away from the mature protem by cellular enzymes A precursor protem, havmg the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation Generally, such precursors are called proproteins In addition to the standard A, G. C. T U representations for nucleic acid bases, the term "N" may also be used in descnbmg certain polynucleotides of the mvention "N" means that any of the four DNA or RNA bases may appear at such a designated position m the DNA or RNA sequence, except it is preferred that N is not a base that when taken in combmation with adjacent nucleotide positions, when read in the correct readmg frame, would have the effect of generatmg a premature termination codon in such reading frame In sum. a polynucleotide of the mvention may encode a mature protem. a mature protem plus a leader sequence (which may be refeπed to as a preprotem). a precursor of a mature protem havmg one or more prosequences that are not the leader sequences of a preprotem- or a preproprote , which is a precursor to a proprotem. havmg a leader sequence and one or more prosequences. which generally are removed during processmg steps that produce active and mature forms of the polypeptide Vectors, host cells, expression The mvention also relates to vectors that compnse a polynucleotide or polynucleotides of the mvention, host cells that are genetically engineered with vectors of the mvention and the production of polypeptides of the mvention by recombinant techniques Cell-free translation systems can also be employed to produce such proteins using RNAs denved from the DNA constructs of the mvention For recombinant production- host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the mvention Introduction of a polynucleotide mto the host cell can be effected by methods descnbed m many standard laboratory manuals, such as Davis et al, BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al . MOLECULAR CLONING A LABORATORY MANUAL. 2nd Ed . Cold Spring Harbor Laboratory Press. Cold Spring Harbor. N Y (1989). such as. calcium phosphate transfection. DEAE-dextran mediated transfection. transvection. nucromjection. cationic lipid- mediated transfection, electroporation. transduction. scrape loading, ballistic mtroduction and infection Representative examples of appropnate hosts mclude bacteπal cells, such as streptococci, staphylococci. enterococci E cob. streptomyces and Bacillus subtihs cells, fiingal cells, such as yeast cells and Aspergillus cells, insect cells such as Drosophila S2 and Spodoptera Sf9 cells, animal cells such as CHO, COS. HeLa. C127. 3T3. BHK. 293 and Bowes melanoma cells, and plant cells A great vaπety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude. among others, chromosomal, episomal and virus-denved vectors. e g . vectors deπved from bacteπal plasmids, from bactenophage. from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenovrruses. fowl pox viruses, pseudorabies viruses and retroviruses. and vectors denved from combinations thereof, such as those denved from plasmid and bactenophage genetic elements, such as cosmids and phagemids The expression system constructs may contain control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide m a host may be used for expression m this regard The appropπate DNA sequence may be inserted mto the expression system by any of a vanety of well-known and routme techniques, such as, for example, those set forth m Sambrook et a . MOLECULAR CLONING, A LABORATORY MANUAL, {supra) For secretion of the translated protem mto the lumen of the endoplasmic reticulum, mto the peπplasmic space or mto the extracellular environment, appropπate secretion signals may be incorporated into the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals Polypeptides of the mvention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography Most preferably, high performance liquid chromatography is employed for purification Well known techmques for refolding protem may be employed to regenerate active confoimation when the polypeptide is denatured during isolation and or purification Diagnostic Assays This mvention is also related to the use of the πbA polynucleotides of the mvention for use as diagnostic reagents Detection of nbA m a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease Eukaryotes (herem also "ιndιvιdual(s)"), particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compπsmg the πbA gene may be detected at the nucleic acid level by a vanety of techmques Nucleic acids for diagnosis ma> be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skm Genomic DNA may be used directly for detection or may be amplified enzymatically by usmg PCR or other amplification technique pπor to anah sis RNA, cDNA and genomic DNA also be used in the same ways Usmg amplification, characterization of the species and sttain of prokaryote present m an individual, may be made an analysis of the genotype of the prokaryote gene Deletions and insertions can be detected by a change m size of the amplified product m compaπson to the genotype of a reference sequence Pomt mutations can be identified by hybπdizmg amplified DNA to labeled nbA polynucleotide sequences Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences m meltmg temperatures DNA sequence differences may also be detected by alterations m the electrophoretic mobilitv of the DNA fragments m gels, with or without denaturing agents, or by direct DNA sequencmg See. e g , Myers et al , Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method See, e g . Cotton et al , Proc Natl Acad Sci , USA, 85 4397-4401 (1985) Cells carrymg mutations or polymorphisms m the gene of the mvention may also be detected at the DNA level by a vanety of techmques, to allow for serotyping, for example For example. RT- PCR can be used to detect mutations It is particularly prefeπed to used RT-PCR m conjunction with automated detection systems, such as. for example, GeneScan RNA, cDNA or genomic DNA may also be used for the same purpose. PCR or RT-PCR As an example, PCR primers complementary to a nucleic acid encodmg nbA can be used to identify and analyze mutations Examples of representative primers are shown below m Table 2 Table 2 Primers for amplification of ribA polynucleotides SEQ ID NO PRIMER SEQUENCE 5 5 ' -ATATGCGCACCAGTGTCTAAAG-3 ' 6 5 ' -CATCGTGCCGTCATCATTCAT-3 ' The mvention also mcludes pπmers of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule. Y is hydrogen or a metal R and R3 is any nucleic acid residue, m is an mteger between 1 and 20 or zero . n is an mteger between 1 and 20 or zero, and R 2 is a primer sequence of the mvention, particularly a primer sequence selected from Table 2 In the polynucleotide formula above R 2 is oπented so that its 5' end residue is at the left, bound to R\ and its 3' end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1. may be either a heteropolymer or a homopolymer. preferably a heteropolymer bemg complementary to a region of a polynucleotide of Table 1 In a prefeπed embodiment m and/or n is an mteger between 1 and 10. The mvention further provides these pπmers with 1, 2. 3 or 4 nucleotides removed from the 5' and/or the 3' end These primers may be used for, among other thmgs, amplifying πbA DNA isolated from a sample denved from an mdividual The primers may be used to amplify the gene isolated from an infected mdividual such that the gene may then be subject to vanous techmques for elucidation of the DNA sequence In this way. mutations in the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent The mvention further provides a process for diagnosing, disease, preferably bactenal infections, more preferably infections by Staphylococcus aureus. compnsmg determinmg from a sample denved from an mdividual a increased level of expression of polynucleotide havmg a sequence of Table 1 [SEQ ID NO 1, 3 or 7] Increased or decreased expression of nbA polynucleotide can be measured usmg any on of the methods well known m the art for the quantation of polynucleotides, such as. for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods In addition, a diagnostic assay m accordance with the mvention for detecting over- expression of πbA protem compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techmques that can be used to determme levels of a πbA protein, m a sample denved from a host are well-known to those of skill m the art Such assay methods mclude radioimmunoassays. competitive-binding assays. Western Blot analysis and ELISA assays Antibodies The polypeptides of the mvention or vanants thereof, or cells expressmg them can be used as an lmmunogen to produce antibodies lmmunospecific for such polypeptides "Antibodies" as used herem mcludes monoclonal and polyclonal antibodies, chimeπc. smgle chain, simianized antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab lmmunolglobuhn expiession library Antibodies generated against the polypeptides of the mvention can be obtained by administering the polypeptides or epitope-beanng fragments, analogues or cells to an animal, preferably a nonhuman, usmg routme protocols For preparation of monoclonal antibodies, any technique known m the art that provides antibodies produced by contmuous cell line cultures can be used Examples mclude vaπous techmques, such as those m Kohler. G and Milstein. C . Nature 256 495-497 (1975), Kozbor et al . Immunology Today 4 72 (1983), Cole et al , pg 77-96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R Liss, fric (1985) Techmques for the production of smgle chain antibodies (U S Patent No 4.946,778) can be adapted to produce smgle chain antibodies to polypeptides of this mvention Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies Alternatively phage display technology may be utilized to select antibody genes w th bindmg activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessmg anti-nbA or from naive libranes (McCafferty, J et al , (1990), Nature 348. 552-554. Marks. J et al , (1992) Biotechnology 10, 779-783) The affinity of these antibodies can also be improved by chain shuffling (Clackson, T et al , (1991) Nature 352, 624-628) If two antigen bmdmg domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify clones expressmg the polypeptides to puπfy the polypeptides by affinity chromatography Thus, among others, antibodies against πbA- polypeptide may be employed to treat infections, particularly bactenal infections Polypeptide variants mclude antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protem or polypeptide according to the mvention. interfere with the immediate physical interaction between pathogen and mammalian host The term "immunologically equivalent derivative" as used herem encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken The fusion protein may provide stability to the polypeptide The antigen be associated, for example by conjugation, with an lmmunogenic carrier protem for example bovme serum albumin (BSA) or keyhole limpet haemocyanm (KLH) Alternatively a multiple antigenic peptide compnsmg multiple copies of the protem or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigemc to improve lmmunogemcity so as to obviate the use of a carnei Preferably, the antibody or variant thereof is modified to make it less lmmunogenic m the mdividual For example, if the individual is human the antibody may most preferabh be "humanized", where the complimentanty determining regιon(s) of the hybndoma-deπved antibody has been transplanted mto a human monoclonal antibody . for example as descnbed in Jones. P et al (1986), Nature 321. 522-525 or Tempest et al . (1991) Biotechnology 9, 266-273 The use of a polynucleotide of the mvention genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA mto muscles (Wolff et al , Hum Mol Genet 1992, 1 363, Manthorpe et al , Hum Gene Ther 1963 4, 419), delivery of DNA complexed with specific protem carriers (Wu et al . J Biol Chem 1989 264,16985), coprecipitation of DNA with calcium phosphate (Benvemsty & Reshef, PNAS USA, 1986 83,9551). encapsulation of DNA m various forms of hposomes (Kaneda et al , Science 1989 243,375). particle bombardment (Tang et al , Nature 1992. 356 152, Eisenbraun et al , DNA Cell Biol 1993, 12 791) and m vivo mfection usmg cloned retroviral vectors (Seeger et al . PNAS USA 1984 81,5849) Antagonists and agonists - assays and molecules Polypeptides of the mvention may also be used to assess the bmdmg of small molecule substrates and hgands in, for example cells, cell-free preparations, chemical braπes, and natural product mixtures These substrates and hgands may be natural substrates and hgands or may be structural or functional mimetics See, e g . Coligan et al , Current Protocols in Immunology 1(2) Chapter 5 (1991) The mvention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of πbA polypeptides or polynucleotides, particularly those compounds that are bacteπostatic and/or bacteπocidal The method of screening may mvolve high-throughput techmques For example, to screen for agonists or antagoists. a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg πbA polypeptide and a labeled substrate or kgand of such polypeptide is mcubated m the absence or the presence of a candidate molecule that may be a πbA agonist or antagonist The ability of the candidate molecule to agomze or antagonize the nbA polypeptide is reflected m decreased bmdmg of the labeled ligand or decreased production of product from such substrate Molecules that b d gratuitously, / e . without mducmg the effects of nbA polypeptide are most likely to be good antagonists Molecules that bmd well and mcrease the rate of product production from substrate are agonists Detection of the rate or level of production of product from substrate may be enhanced by usmg a reporter system Reporter systems that may be useful in this regard mclude but are not limited to colonmetπc labeled substrate converted mto product, a reporter gene that is responsive to changes m nbA polynucleotide or polypeptide activity, and bmdmg assays known m the art Another example of an assay for nbA antagonists is a competitive assay that combmes nbA and a potential antagonist with nbA-binding molecules, recombinant nbA bmdmg molecules, natural substrates or hgands, or substrate or gand immetics, under appropπate conditions for a competitive inhibition assay The nbA molecule can be labeled, such as by radioactivity or a coloπmetπc compound, such that the number of nbA molecules bound to a bmdmg molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist Potential antagonists mclude small organic molecules, peptides, polypeptides and antibodies that bmd to a polynucleotide or polypeptide of the mvention and thereby inhibit or extinguish its activity Potential antagonists also may be small organic molecules, a peptide. a polypeptide such as a closely related protem or antibody that bmds the same sites on a bmdmg molecule, such as a bmdmg molecule, without mducmg nbA-induced activities, thereby preventing the action of πbA by excluding πbA from bmdmg Potential antagonists mclude a small molecule that bmds to and occupies the bmdmg site of the polypeptide thereby preventing bmdmg to cellular bmdmg molecules, such that normal biological activity is prevented Examples of small molecules mclude but are not limited to small organic molecules, peptides or peptide-like molecules Other potential antagonists mclude antisense molecules (see Okano, J Neurochem 56 560 (1991), OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press. Boca Raton, FL (1988). for a descnption of these molecules) Prefeπed potential antagonists mclude compounds related to and vanants of πbA Each of the DNA sequences provided herem may be used m the discovery and development of antibacterial compounds The encoded protem, upon expression, can be used as a target for the screening of antibacterial drugs Additionally, the DNA sequences encodmg the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facihtatmg sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest The invention also provides the use of the polypeptide. polynucleotide or inhibitor of the mvention to interfere with the initial physical mteraction between a pathogen and mammalian host responsible for sequelae of infection In particular the molecules of the mvention may be used m the prevention of adhesion of bactena, in particular gram positive bactena. to mammalian extracellular matrix proteins on m-dwellmg devices or to extracellular matrix protems m wounds, to block nbA protem-mediated mammalian cell mvasion by. for example, initiating phosphorylation of mammalian tyrosme kmases (Rosenshine et al , Infect Immun 60.2211 (1992), to block bactenal adhesion between mammalian extracellular matnx protems and bactenal nbA protems that mediate tissue damage and, to block the normal progression of pathogenesis in infections initiated other than by the implantation of m-dwellmg devices or by other surgical techmques The antagonists and agonists of the mvention may be employed, for instance, to inhibit and treat diseases Hehcobacter pylori (herem H pylon) bacteria infect the stomachs of over one-third of the world's population causmg stomach cancer, ulcers, and gastπtis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Hehcobacter Pylori (International Agency for Research on Cancer, Lyon. France, http //www uicc ch/ecp/ecp2904 htm) Moreover, the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H pylori and gastric adenocarcmoma. classifying the bacterium as a Group I (definite) carcmogen Preferred antimicrobial compounds of the mvention (agonists and antagonists of πbA) found usmg screens provided by the mvention, particulaily broad- spectrum antibiotics, should be useful m the treatment of H pylori infection Such treatment should decrease the advent of H /?v/oπ -induced cancers, such as gastrointestinal carcinoma Such treatment should also cure gastric ulcers and gastritis Vaccines Another aspect of the invention relates to a method for mducmg an unmunological response m an individual, particularly a mammal which comprises inoculating the individual with nbA, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said mdividual from infection, particularly bacterial mfection and most particularly Staphylococcus aureus infection Also provided are methods whereby such rmmunological response slows bactenal replication Yet anothei aspect of the invention relates to a method of mducmg unmunological response in an mdividual which comprises delivering to such mdividual a nucleic acid vector to direct expression of nbN or a fragment or a vaπant thereof, for expressmg nbA, or a fragment or a variant thereof in vivo m order to mduce an unmunological response, such as, to produce antibody and/ or T cell immune response, mcludmg. for example, cytokme-producmg T cells or cytotoxic T cells, to protect said mdividual from disease, whether that disease is already established within the individual or not One way of administering the gene is by acceleratmg it mto the desired cells as a coatmg on particles or otherwise Such nucleic acid vector may compnse DNA, RNA, a modified nucleic acid, or a DNA/RNA hybnd A further aspect of the mvention relates to an lmmunological composition which, when mtroduced mto an mdividual capable or havmg induced within it an immunological response, mduces an immunological response in such mdividual to a nbA or protem coded therefrom, wherem the composition compnses a recombinant nbA oi protem coded therefrom compnsmg DNA which codes foi and expresses an antigen of said πbA or protem coded therefrom The unmunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells A nbA polypeptide or a fragment thereof may be fused with co-protem which may not by itself produce antibodies, but is capable of stabilizing the fiist protein and producmg a fused protein which will have lmmunogenic and protective properties Thus fused recombinant protein, preferably further comprises an antigenic co-piotem. such as hpoprotem D from Hemophilus influenzae. Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-protems which solubihze the protein and facilitate production and purification thereof Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system The co-protein may be attached to either the ammo or carboxy terminus of the first protem Provided by this invention are compositions, particularly vaccine compositions, and methods compnsmg the polypeptides or polynucleotides of the invention and lmmunostimulatoiy DNA sequences, such as those descnbed m Sato. Y et al Science 273 352 (1996) Also, provided by this invention are methods using the described polynucleotide oi particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immumzation experiments m animal models of mfection with Staphylococcus aureus will be particularly useful for identifying protem epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resistmg or cleanng mfection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Staphylococcus aureus infection, m mammals, particularly humans The polypeptide may be used as an antigen for vaccmation of a host to produce specific antibodies which protect agamst invasion of bactena, for example by blocking adherence of bactena to damaged tissue Examples of tissue damage mclude wounds m skm or connective tissue caused, e g , by mechanical, chemical or thermal damage or by implantation of mdwellmg devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagma The invention also includes a vaccine formulation which comprises an lmmunogenic recombinant protem of the mvention together with a suitable earner Smce the protem may be broken down in the stomach, it is preferably administered parenterally, mcludmg, for example, administration that is subcutaneous, intramuscular, intravenous, or mtradermal Formulations suitable for parenteral administration mclude aqueous and non-aqueous steπle injection solutions which may contain anti-oxidants. buffeis. bacteπostats and solutes which render the formulation msotomc with the bodily fluid, preferably the blood, of the mdividual, and aqueous and non-aqueous sterile suspensions which may mclude suspending agents or thickening agents The formulations may be presented in unit-dose or multi-dose contamers. for example, sealed ampules and vials and may be stored a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use The vaccme formulation may also mclude adjuvant systems for enhancing the lmmunogenicity of the foimulation, such as oil-in wate systems and other systems known m the art The dosage will depend on the specific activity of the vaccme and can be readily determined by routine experimentation While the invention has been descnbed with reference to certain nbA protem, it is to be understood that this covers fragments of the naturally occurrmg protein and similar protems with additions, deletions oi substitutions which do not substantially affect the lmmunogenic properties of the recombinant protem Compositions, kits and administration The mvention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agonists or antagonists The polypeptides of the mvention may be employed m combination with a non-stenle or sterile earner or earners for use with cells, tissues oi organisms, such as a pharmaceutical earner suitable for administration to a subject Such compositions compnse. for instance, a media additive or a therapeutically effective amount of a polypeptide of the mvention and a pharmaceutically acceptable earner or excipient Such earners may mclude, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof The formulation should suit the mode of administration The mvention further relates to diagnostic and pharmaceutical packs and kits compπsmg one or more contamers filled with one or more of the ingredients of the aforementioned compositions of the mvention Polypeptides and other compounds of the mvention may be employed alone or m conjunction with othe compounds, such as therapeutic compounds The pharmaceutical compositions may be administered m any effective, convement manner mcludmg, for instance, administration by topical, oral, anal, vaginal, mtravenous, mtrapeπtoneal, intramuscular, subcutaneous, intranasal or mtradermal routes among others In therapy or as a prophylactic, the active agent may be administered to an mdividual as an mjectable composition, for example as a sterile aqueous dispersion, preferably isotomc Alternatively the composition may be formulated for topical application for example m the form of omtments. creams, lotions, eye omtments, eye drops, ear drops, mouthwash. impregnated dressmgs and sutures and aerosols, and may contam appropnate conventional additives, mcludmg, for example, preservatives, solvents to assist drug penetration, and emollients in omtments and creams Such topical formulations may also contam compatible conventional carne s, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions Such earners may constitute from about 1% to about 98% by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mg/kg to 10 mg/kg, typically around 1 mg/kg The physician in any event will determme the actual dosage which will be most suitable for an mdividual and will vaiy with the age, weight and response of the particular individual The above dosages are exemplary of the average case There can, of course, be mdividual mstances where higher or lower dosage ranges are mented. and such are withm the scope of this mvention In-dwelling devices mclude su gical implants, prosthetic devices and catheters, l e , devices that are mtroduced to the body of an individual and remam m position for an extended time Such devices mclude, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospmal fluid shunts, unnary catheters, contmuous ambulatory peritoneal dialysis (CAPD) catheters The composition of the invention may be administered by injection to achieve a systemic effect against relevant bactena shortly before insertion of an m-dwellmg device Treatment may be continued after surgery during the m-body tune of the device In addition, the composition could also be used to broaden penoperatrve cover for any surgical technique to prevent bactenal wound infections, especially Staphylococcus aureus wound infections Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia Late deep mfection is a serious complication sometimes leadmg to loss of the prosthetic joint and is accompanied by significant morbidity and mortality It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation In addition to the therapy descnbed above, the compositions of this mvention ma be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use m dental treatment as an alternative to, or m conjunction with, antibiotic prophylaxis Alternatively, the composition of the invention may be used to bathe an mdwellmg device immediately before insertion The active agent will preferably be present at a concentration of lμg/ml to lOmg/ml for bathing of wounds o indwelling devices A vaccine composition is conveniently in mjectable form Conventional adjuvants may be employed to enhance the immune response A suitable unit dose for vaccination is 0 5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks With the mdicated dose lange. no adveise toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals Each reference disclosed herem is incorporated by reference herein m its entirety Any patent application to which this application claims priority is also incorporated by reference herein in its entirety GLOSSARY The following definitions are provided to facilitate understanding of certain terms used frequently herem "Dιsease(s)" means and disease caused by or related to infection by a bactena, mcludmg disease, such as. infections of the upper respiratory tract (e g . otitis media, bactenal tiacheitis. acute epiglottitis. thyroiditis). lower respiratory (e g . empyema. lung abscess), cardiac (e g , infective endocarditis), gastrointestinal (e g . secretory diaπhoea, splenic absces, retropentoneal abscess), CNS (e g , cerebral abscess), eye (e g . blephaπtis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellu-itis, darcryocystitis). kidney and urinary tract (e g , epididyrmtis. rntrarenal and pennephnc abscess, toxic shock syndrome), skm (e g , impetigo, fol-icu tis. cutaneous abscesses, cellulitis, wound infection, bactenal myositis) bone and jomt (e g , septic arthntis, osteomyelitis) "Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence "Identity," as known m the art. is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determmed by compaπng the sequences In the art. "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match betw een strings of such sequences "Identity" and "similanty" can be readi calculated by known methods, mcludmg but not limited to those described in {Computational Molecular Biology, Lesk, A M , ed , Oxford University Press. New York. 1988, Biocomputing Informatics and Genome Projects. Smith, D W . ed . Academic Press, New York. 1993. Computer Analysis of Sequence Data. Part I. Gnffin. A M , and Gnffin, H G . eds . Humana Press, New Jersey . 1994, Sequence Analysis n Molecular Biology, von Hemje. G . Academic Press, 1987, and Sequence Analysis Primer. Gnbskov, M and Devereux, J , eds , M Stockton Press, New York, 1991, and Caπllo. H . and Lipman, D , SIAM J Applied Math , 48 1073 (1988) Preferred methods to determme identity are designed to give the largest match between the sequences tested Methods to determme identity and similarity are codified in publicly aλailable computer programs Preferred computer program methods to determme identity and similarity between two sequences mclude. but are not limited to. the GCG program package (Devereux. J , et al . Nucleic Acids Research 12(1) 387 (1984)). BLASTP, BLASTN. and FASTA (Atschul. S F et al , J Molec Biol 215 403-410 (1990) The BLAST X program is publicly available from NCBI and other sources {BLAST Manual, Altschul. S . et al , NCBI NLM NIH Bethesda. MD 20894. Altschul, S . et al . J Mol Biol 215 403-410 (1990) As an illustration, by a polynucleotide havmg a nucleotide sequence having at least, for example. 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may mclude up to five pomt mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1 In other words, to obtain a polynucleotide havmg a nucleotide sequence at least 95 % identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide. or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted mto the reference sequence These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence oi anywhere between those terminal positions, mterspersed either individually among nucleotides m the reference sequence or in one or more contiguous groups withm the reference sequence Analogously , by a polypeptide havmg an ammo acid sequence havmg at least, for example. 95% identity to a reference ammo acid sequence of SEQ ID NO 2 is mtended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may mclude up to five amino acid alterations per each 100 ammo acids of the reference ammo acid of SEQ ID NO 2 In other words, to obtain a polypeptide havmg an amino acid sequence at least 95% identical to a reference ammo acid sequence, up to 5% of the ammo acid residues m the reference sequence may be deleted or substituted with another ammo acid, or a number of ammo acids up to 5% of the total ammo acid residues in the reference sequence may be inserted into the reference sequence These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference ammo acid sequence or anywhere between those terminal positions, interspersed either mdividuallv among residues in the reference sequence or in one or more contiguous groups withm the reference sequence "Isolated" means altered "by the hand of man" from its natural state, i e , if it occurs m nature, it has been changed or removed from its onginal environment, or both For example, a polynucleotide or a polypeptide naturally present m a living organism is not "isolated, " but the same polynucleotide or polypeptide separated from the coexistmg matenals of its natural state is "isolated", as the term is employed herem Moreover, a polynucleotide or polypeptide that is mtroduced mto an organism by tiansformation. genetic manipulation or by any other recombinant method is "isolated" even if it is still present m said organism, which organism may be living or nonliving "Polynucleotide(s)" generally refers to any polyπbonucleotide or polydeoxπbonucleotide, which be unmodified RNA or DNA or modified RNA or DNA "Polynucleotide(s)" mclude. without limitation, smgle- and double-stranded DNA, DNA that is a mixture of smgle- and double- stranded regions or single-, double- and tnple-stranded regions, smgle- and double-stranded RNA, and RNA that is mixture of smgle- and double-stranded regions, hybπd molecules compnsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of single- and double-stranded regions In addition, "polynucleotide" as used herem refers to tnple-stranded regions compnsmg RNA or DNA or both RNA and DNA The strands m such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically mvolve only a region of some of the molecules One of the molecules of a tnple-hehcal region often is an oligonucleotide As used herem, the term "polynucleotide(s)" also mcludes DNAs or RNAs as descnbed above that contam one or more modified bases Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is mtended herem Moreover, DNAs or RNAs compnsmg unusual bases, such as mosme. or modified bases, such as tntylated bases, to name just two examples, are polynucleotides as the teim is used herem It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill m the art The term "polynucleotide(s)" as it is employed herem embraces such chemically, enzymatically or metabolically modified forms of polynucleotides. as well as the chemical forms of DNA and RNA characteπstic of viruses and cells, mcludmg, for example, simple and complex cells "Polynucleotide(s)" also embraces short polynucleotides often refeπed to as ohgonucleotide(s) "Polypeptide(s)" refers to any peptide or protem compπsmg two or more ammo acids joined to each other by peptide bonds or modified peptide bonds "Poh eptide(s)" refers to both short chains, commonly refeπed to as peptides. o gopeptides and ohgomeis and to longer chains generally refeπed to as proteins Polypeptides may contam ammo acids other than the 20 gene encoded ammo acids "Polypeptide(s)" mclude those modified either by natural processes, such as processmg and other post-translational modifications, but also by chemical modification techmques Such modifications are well descnbed m basic texts and m more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill m the art It will be appreciated that the same type of modification may be present m the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may contam many types of modifications Modifications can occui anywhere m a polypeptide. mcludmg the peptide backbone, the ammo acid side-chains, and the ammo or carboxyl termini Modifications mclude. for example, acetylation. acylation, ADP-nbosylation, amidation. covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide denvative, covalent attachment of a pid or hpid denvative, covalent attachment of phosphotidylinositol, cross-linking, cychzation. disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate. formylation, gamma-carboxylation, glycosylation. GPI anchor formation, hydroxylation, lodination, methylation. mynstoylation, oxidation, proteolytic processmg, phosphorylation, prenylation, racemization, glycosylation, hpid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-nbosylation, selenoylation, sulfation, transfer-RNA mediated addition of ammo acids to proteins, such as arginylation. and ubiquitination See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed , T E Creighton, W H Freeman and Company, New York (1993) and Wold. F , Posttranslational Protem Modifications Perspectives and Prospects, pgs 1-12 m POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B C Johnson. E . Academic Press, New York (1983), Softer et al , Meth Enzymol 182 626-646 (1990) and Rattan et al . Protem Synthesis Posttranslational Modifications and Aging, Ann N Y Acad Sci 663 48- 62 (1992) Polypeptides may be blanched or cyclic, with or without branching Cyclic, blanched and branched circular polypeptides may result from post-translational natural processes and be made by entirely synthetic methods, as well 'Nanant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties A typical vanant of a polynucleotide differs m nucleotide sequence from another, reference polynucleotide Changes m the nucleotide sequence of the variant may or may not alter the ammo acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result m ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below A typical vanant of a polypeptide differs m ammo acid sequence from another, reference polypeptide Generally, differences are limited so that the sequences of the reference polypeptide and the vanant are closely similar overall and, in many regions, identical A vanant and reference polypeptide may differ m ammo acid sequence one or more substitutions, additions, deletions m an> combination A substituted or inserted amino acid residue may or may not be one encoded by the genetic code A vanant of a pohnucleotide or polypeptide may be a naturally occurrmg such as an allelic variant, or it may be a variant that is not known to occur naturally Non- naturally occurrmg variants of polynucleotides and polypeptides may be made by mutagenesis techmques, by direct synthesis, and by other recombinant methods known to skilled artisans EXAMPLES The examples below are earned out usmg standard techmques, which are well known and routme to those of skill m the art. except where otherwise descnbed m detail The examples are illustrative, but do not limit the mvention Example 1 Strain selection, Library Production and Sequencing The polynucleotide havmg a DNA sequence given m Table 1 [SEQ ID NO 1, 3 or 7] was obtained from a library of clones of chromosomal DNA of Staphylococcus aureus m E cob The sequencmg data from two or more clones contammg overlappmg Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence m SEQ ID NO 1 Libranes may be prepared by routme methods, for example Methods 1 and 2 below Total cellular DNA is isolated from Staphylococcus aureus WCUH 29 according to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle m order to size-fractionate according to standard procedures DNA fragments of up to 1 lkbp m size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added Fragments are ligated mto the vectoi Lambda ZapII that has been cut with EcoRI. the library packaged by standard procedures and E cob infected with the packaged library The library is amplified by standard procedures Method 2 Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropnate to generate a series of fragments for clomng mto library vectors (e g . Rsal. Pall. Alul. Bshl235I). and such fragments are size-fractionated accordmg to standard procedures EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E cob infected with the packaged library The library is amplified by standard procedures Example 2 ribA Characterization Characterization of Staphylococcus aureus ribA Gene Expression Gene expression in vivo Recently several novel approaches have been descnbed which purport to follow global gene expression during mfection (Chuang. S et al , (1993), Mahan, M J et al , Science 259 686-688 (1993), Hensel, M et al . Science 269 400-403 (1995) These new techmques have so far been demonstrated with gram negative pathogen infections but not with infections with gram positives presumably because the much slower development of global transposon mutagenesis and suitable vectors needed for these strategies m these organisms, and m the case of that process descnbed by Chuang. S et al , J Bacterwl 775 2026-2036 (1993) the difficulty of isolatmg suitable quantities of bacterial RNA free of mammalian RNA denved from the mfected tissue to furnish bacterial RNA labelled to sufficiently high specific activity The present mvention employs a novel technology to determme gene expression m the pathogen at different stages of infection of the mammalian host Use of the technology of the present invention enables identification of bacterial genes transcribed during mfection, inhibitors of which would have utility in anti-bactenal therapy Specific inhibitors of such gene transcπption or of the subsequent translation of the resultant mRNA or of the function of the coπespondmg expressed protems would have utility m antibacterial therapy The determination of expression during infection of a gene from Staphylococcus aureus WCUH29 Necrotic fatty tissue from a four day grom mfection or kidney from a seven day pyelonephntis infection of Staphylococcus aureus WCUH29 m the mouse is efficiently disrupted and processed in the presence of acid phenol and detergent to provide a mixture of anunal and bactenal RNA By freezing the tissue immediately in liquid mtrogen. and processmg the tissue samples while still frozen, changes in the population of bacterial mRNA is minimized The resultant total RNA is free of DNA and protein (including RNAases and DNAases) The optimal conditions for disruption and processmg to give high yields of bacterial mRNA with transcnpts of long length are followed by reverse transcribing the resultmg mRNA to cDNA and amplified with ORF-specific primers for a bactenal gene known to be expressed constitutively and at low copy numbe in Staphylococcus aureus WCUH29 Aspects of this example II, part b. are modifications of a published protocol (Cheung, et al , Anal Biochem (1994) 222 511-514) a) Isolation of tissue infected with Staphylococcus aureus WCUH29 from urine models of infection 1) Isolation of tissue infected with Staphylococcus aureus WCUH29 from a murine thigh lesion model of infection 10 ml volumes of sterile nutnent broth (No 2 Oxoid) are seeded with isolated, mdividual colonies of Staphylococcus aureus WCUH29 from an agar culture plate The cultures are mcubated aerobically (static culture) at 37°C for 16-20 hours 4 week old mice (female, 18g-22g, stram MF1) are each infected by subcutaneous injection of 0 5ml of this broth culture of Staphylococcus aureus WCUH29 (diluted m broth to approximately 10° cfu/ml ) mto the antenor , nght lower quadrant (grom area) Mice should be monitored regularly dunng the first 24 hours after infection, then daily until termination of study Animals with signs of systemic infection, l e lethargy, ruffled appearance, isolation from group, should be momtored closely and if signs progress to monbundancy, the animal should be culled immediately Visible external signs of lesion development will be seen 24-48h aftei infection Examination of the abdomen of the animal will show the raised outlme of the abscess beneath the skm The localised lesion should remain m the right lower quadrant, but may occasionally spread to the left lower quadrant, and supeπorly to the thorax On occasions, the abscess may rupture through the overlymg skm layers In such cases the affected anunal should be culled immediately and the tissues sampled if possible Failure to cull the animal may result in the necrotic skm tissue overlymg the abscess bemg sloughed off. exposing the abdommal muscle wall Approximately 96 hours after infection animals are killed usmg carbon dioxide asphyxiation To minimise delay between death and tissue processing /storage, mice should be killed individually rather than in groups The dead animal is placed onto its back and the fin swabbed liberally with 70% alcohol An initial incision using scissors is made through the skm of the abdommal left lower quadrant, travelling supeπorh up to. then across the thorax The incision is completed by cuttmg mfenoily to the abdommal lower right quadrant Care should be taken not to penetrate the abdommal wall Holding the skin flap with forceps, the skm is gently pulled way from the abdomen The exposed abscess which covers the pentoneal wall but generally does not penetrate the muscle sheet completely, is excised, taking care not to puncture the viscera The abscess/muscle sheet and other infected tissue may require cuttmg m sections, prior to flash-freezing in liquid mtrogen, thereby allowing easier storage in plastic collecting vials n) Isolation of tissue infected with Staphylococcus aureus WCUH29 from a murine model of hematogenous pyelonephritis Overnight cultures of S aureus WCUH29 were started from smgle colonies m 5 ml of tryptic sov broth (TSB) and grown at 37C with shaking The cultures were then washed twice m sterile phosphate-buffered salme (PBS) and diluted to an A600 = 0 3 Male CD-I mice (18 - 20g) were infected with 0 2 ml of this suspension by tail vem inoculation usmg a 30g needle attached to a tuberculin syringe Each mouse receives approximately 4 x 107 bacteria in this fashion Mice are momtored daily for signs of illness, and usually withm 48 houis show signs of lethargy, ruffled fur, sluggishness, animals which appear moribund are euthanized prior to the end of the experiment All animals are euthanized via carbon dioxide overdose seven days post-infection The animal is placed on its back and swabbed with ethanol, and then with RNAZap. and instruments are swabbed as well The abdommal cavity is opened and the kidneys aseptically removed, cut mto four pieces, and placed in cryovials which are immediately frozen m liquid mtrogen b) Isolation of Staphylococcus aureus WCUH29 RNA from infected tissue samples Infected tissue samples, m 2-ml cryo-strorage tubes, are removed from liquid mtrogen storage for immediate processmg of the frozen tissue In a microbiological safety cabmet the samples are disrupted up to eight at a tune To disrupt the bacteria withm the tissue sample, 50-100 mg of the tissue is transfered to a FastRNA tube contammg a silica ceramic matπx (BIOlOl) Immediately, 1 ml of extraction reagents (FastRNA reagents, BIO 101) are added to give a sample to reagent volume ratio of approximately 1 to 20 The tubes are shaken m a reciprocatmg shaker (FastPrep FP120. BIOlOl) at a setting of 5 5 to 6 for 20-120 sec The crude RNA preparation is extracted with chloroform/isoamyl alcohol, and precipitated with DEPC-treated/Isopropanol Precipitation Solution (BIOlOl) RNA preparations are stored m this isopropanol solution at -80°C if necessary The RNA is pelleted (12.000g for 10 mm ), washed with 75% ethanol (v/v m DEPC-treated water), air-dried for 5-10 nun and resuspended in 0 1 ml of DEPC-treated water Quality of the RNA isolated is assessed by the ability to detect bacterial transcnpts up to 2 kb m length by RT-PCR (as descnbed in section below) To demonstrate the isolation of bactenal RNA from the infected tissue, samples of RNA are reverse transcribed, and the presence of a constitutively expressed gene is detected through the use of quantitative PCR in the presence of a TaqMan probe (as described below) c) The removal of DNA from Staphylococcus aureus WCUH29-derived RNA DNA was removed from 50 microgram samples of RNA by a 30 mmute treatment at 37°C with 10 units of RNAase-free DNAasel (GeneHunter) m the buffer supplied m a final volume of 57 microhters The DNAase was mactivated and removed by phenol chloroform extraction RNA was precipitated with 5 microhters of 3 M NaOAc and 200 microliters 100% EtOH. and pelleted by centπfugation at 12,000g for 10 minutes The RNA is pelleted (12,000g for 10 mm ), washed with 75% ethanol (v/v in DEPC-treated water), air-dπed for 5-10 mm. and resuspended m 10-20 microhters of DEPC-treated water RNA yield is quantitated by OD 2 Q after 1 1000 dilution of the cleaned RNA sample RNA is stored at -80°C if necessary and reverse-transcribed withm one week d) The preparation of cDNA from RNA samples derived from infected tissue 10 microliter samples of DNAase treated RNA are reverse transcribed usmg a Superscript Preamplification System for First Strand cDNA Synthesis kit (Gibco BRL. Life Technologies) according to the manufacturers instructions 1 nanogram of random hexamers is used to prime each reaction Controls without the addition of SuperScπptll everse transcnptase are also run Both +/-RT samples are treated with RNaseH before proceedmg to the PCR reaction e) The use of PCR to determine the quality of bacterial RNA derived from infected tissue Long transcπpts. which are expected to be of low copy number withm the bacterial cell, such as penicillm-bmdmg protem 2 (PBP2), are reverse transcribed with random primers as described above and amplified by the following PCR method using ORF-specific primers, m order to ascertain the quality, represented by length amplified of the mRNA obtained during extraction and punfication PCR reactions are set up on ice in 0 2 ml tubes m a total volume of 50 ul by adding the following components [final concentration] AmphTaq PCR Buffer II (IX), 1 5mM MgCL 1 mM dNTPs. 0 5uM forward primer, 0 5uM reverse primer, and 2 ul reverse-transcribed RNA PCR reactions are run on a PE GeneAmp PCR System 9600 with an initial step of 94°C for 2mm, followed by 35 cycles of 94 °C for 30sec, 42 °C for 30sec and 72 °C for 30sec, followed bv a final extensison at 72 °C for 7mm f) The use of PCR to determine the presence of a bacterial cDNA species PCR reactions are set up as described above using 0 5 microM each of the ORF specific forward and reverse primers PCR product in 20 microliter ahquots are separated bv electrophoresis through 1 to 1 5% 1 x TBE agarose gels or 10% lx TBE acrylamide gels PCR product is visualized by stainmg the gel with ethidium bromide Size estimates are made bv companson to a 100 bp DNA Ladder (Gibco BRL, Life Technologies) Alternatively, if the PCR products are convemently labelled by the use of a labelled PCR primer (e g labelled at the 5'end with a dye) a suitable aliquot of the PCR product is run out on a polyacrylamide sequencmg gel and its presence and quantity detected usmg a suitable gel scanning system (e g ABI PnsmTM 377 Sequencer usmg GeneScan^M software as supplied by Perkin Elmer) RT PCR controls may mclude +/- reverse transcnptase reactions, 16s rRNA primers or DNA specific primer pairs designed to produce PCR products from non-transcnbed Staphylococcus aureus WCUH29 genomic sequences To test the efficiency of the primer pairs they are used in DNA PCR with Staphylococcus aureus WCUH29 total DNA PCR reactions are set up and run as descnbed above usmg approx 1 microgram of DNA in place of the cDNA and 35 cycles of PCR Primer pairs which fail to give the predicted sized product m either DNA PCR or RT/PCR are PCR failures and as such are uninformative Of those which give the correct size product with DNA PCR two classes are distinguished m RT/PCR 1 Genes which are not transcribed in vivo reproducibly fail to give a product in RT/PCR. and 2 Genes which are transcribed in vivo reproducibly give the correct size product in RT/PCR and show a stronger signal in the +RT samples than the signal (if at all present) m -RT controls g) The use of PCR and fluorogenic probes to determine the presence of a bacterial cDNA species Specific sequence detection occurs by amplification of target sequences m the PE Applied Biosystems 7700 Sequence Detection System in the presence of an oligonucleotide probe labeled at the 5' and 3' ends with a reporter and quencher fluorescent dye. respectively (FQ probe), which anneals between the two PCR primers Only specific product will be detected when the probe is bound between the primers As PCR amplification proceeds, the 5'- nuclease activity of Taq polymerase mitially cleaves the reporter dye from the probe The signal generated when the reporter dye is physically separated from the quencher dye is detected by measunng the signal with an attached CCD camera Each signal generated equals one probe cleaved which corresponds to amplification of one target strand PCR reactions are set up usmg the PE Applied Biosystem TaqMan PCR Core Reagent Kit accordmg to the mstructions supplied such that each reaction contains 5 microhters 10X PCR Buffer II, 7 microhters 25 mM MgCl 2 . 5 microhters 300 nM forward primer. 5 microhters reverse primer. 5 microhters specific FQ probe, 1 microliter each 10 mM dATP. 10 mM dCTP. 10 mM dGTP and 20 mM dUTP. 13 25 microhters distilled water, 0 5 microhters AmpErase UNG. and 0 25 microhters AmphTaq DNA polymerase to give a total volume of 45 microhters Amplification proceeds under the following thermal cycling conditions 50°C hold for 2 rmnutes, 95 °C hold for 10 mmutes, 40 cycles of 95 °C for 15 seconds and 60°C for 1 mmute, followed by a 25 °C hold until sample is retrieved Detection occurs real-time Data is collected at the end of the reaction Based on these analyses it was discovered that the Staphylococcus aureus nbA gene was transcnbed in vivo Riboflavin Biosynthesis Operon This ORF is part of an operon which encodes genes rib G, nbB, nbA and nbH Gene ribG starts at nucleotide 1 and ends at nucleotide 1029 Gene bB starts at nucleotide 1036 and ends at nucleotide 1668 Gene nbA starts at nucleotide 1679 and ends at nucleotide 2860 Gene nbH starts at nucleotide 2873 and ends at nucleotide 3337 This operon [SEQ ID NO 7] is as follows ATGGATTATGCGATTCAACTTGCAAATATGGTACAAGGTCAAACAGGTGTTAATCCACCCGTTGGCGCT GTTGTAGTTAATGAAGGTAGGATTGTTGGTATTGGTGCACACTTGAGAAAAGGTGACAAGCATGCGGAG GTTCAAGCACTTGATATGGCACAACAAAATGCTGAAGGTGCGACGATTTATATTACGTTAGAGCCATGT AGTCATTTTGGTTCAACACCACCCTGTGTTAACAAAATTATTGATTGTAAGATAGCAAAAGTAGTATAC GCAACAAAAGACAATTCGTTAGACACACATGGTGATGAGACGTTACGGGCTCACGGTATTGAGGTTGAA TGCGTTGATGATGAACGGGCATCACAATTATACCAAGACTTTTTTAAAGCAAAAGCAAAGCAACTGCCA CAAATTACAGTGAAAGTATCTGCAAGTTTAGATGGTAAACAAGCGAATGATAATGGACAAAGTCAATGG ATTACTAACAAAGAGGTTAAACAAGATGTCTATAAGTTAAGACATCGACACGACGCAGTGTTAACTGGA AGACGTACAGTTGAATTAGATGATCCACAATATACTACACGTATTCAAGATGGAAAAAACCCTATAAAA GTAATATTGTCTAAGTCTGGGAATATTCATTTTAATCAGCAAATTTATCAAGATGAATCAACACCAATT TGGATATATACTGAAAATCCAAATTTAACAAGCAATCAAACACATATTGAAATTATTTACTTGAAGTCT TGTGATTTAACAACAATTCTTCACAATTTATATAAAAGAGGAGTTGGAACTTTGCTAGTCGAGGCAGGT CCAACCACTACTTCAGAATTCTCCATCTATTATATAGATGAATTTATTCTCTATTATGCCCCGAAATTA ATTGGCGGATCTGGAAATTATCAATTTTATCAAACAAATGATGTGATTGAGATACCAGATGCGAACCAA TTTGAAATTGTTCATTCCGAGTTATTAAATCAAAATGTTAAATTAACTTTACGAAAGAAGTGATGATGC ATGTTTACTGGCATCGTTGAAGAAATAGGTGTCGTTAAAAGTGTTCAAATTCGTCAATCAGTCAGGACG ATTGAAATCGAAGCACATAAGATTACGGCAGATATGCATATTGGTGATTCCATCAGTGTTAATGGTGCA TGTTTAACAGTGATTGATTTTGATCAGACATCTTTTACTGTTCAAGTAATTAAAAGCACTGAAAATAAA ACCTATTTAGCAGATGTTAAGCGACAATCAGAAGTAAATTTAGAGCGTGCCATGAGTGGTAACGGTAGG TTTGGTGGACATTTTGTCCTCGGTCATGTAGATGAACTAGGAACAGTTT CAAAAATAAATGAAACAGCCAATGCCAAAATTATTACGATTCAATGTAGCCAACATATTAATAATCAGT TAGTTAAGCAAGGGTCTATTACTGTGGATGGTGTAAGTCTAACGGTATTTGATAAGCATGATAACAGTT TTGACATTCATCTTATTCCAGAAACGAGGCGTTCAACGATTTTATCATCCAAAAAATTAGGAGATAAAG TACATTTAGAAACAGACGTTTTGTTTAAATATGTTGAAAATATTTTAAATAAAGATAAAGACCAATTAT CTGTAGATAAATTAAGAGCATTTGGTTTTTAGGAGGGGTAGCATGCAATTCGATAATATTGACAGTGCT TTAATGGCTTTAAAAAATGGAGAAACAATTATTGTAGTAGATGATGAGAATCGTGAAAATGAAGGTGAT TTAGTAGCGGTTACTGAATGGATGAACGATAATACCATTAATTTTATGGCGAAAGAAGCAAGGGGATTA ATATGCGCACCAGTGTCTAAAGATATTGCACAACGTTTGGATTTGGTACAAATGGTTGATGATAACTCC GACATCTTTGGTACGCAATTTACAGTGAGTATTGATCATGTAGATACAACAACAGGAATTAGTGCTTAT GAACGTACATTGACTGCCAAAAAGCTCATTGATCCTAGTAGTGAAGCTAAAGATTTTAATCGTCCTGGT CATTTATTTCCATTAGTAGCACAAGATAAAGGCGTATTAGCTAGAAATGGACACACAGAAGCGGCTGTT GATTTAGCTAAACTTACTGGTGCCAAGCCCGCTGGTGTCATTTGTGAGATTATGAATGATGACGGCACG ATGGCGAAAGGACAAGATTTACAAAATTTTAAAGAAAAACATCAATTAAAGATGATTACGATTGATGAT TTAATTGAATATCGTAAAAAATTAGAACCAGAAATTGAATTTAAGGCAAAAGTGAAAATGCCTACAGAT TTCGGAACATTTGATATGTATGGTTTTAAAGCGACATACACAGATGAAGAGATAGTTGTACTGACAAAA GGTGCAATTCGACAACATGAAAATGTACGCTTACATTCTGCGTGCCTTACAGGCGATATTTTCCATAGT CAACGTTGTGATTGTGGTGCTCAACTTGAATCGTCTATGAAGTATATCAATGAACATGGTGGCATGATT ATTTATCTACCTCAAGAAGGTCGTGGCATAGGATTGTTAAACAAATTACGCGCATATGAATTAATTGAG CAAGGATATGATACAGTAACTGCAAATTTAGCATTAGGTTTTGATGAAGATTTACGAGATTATCATATT GCTGCACAGATTTTAAAATATTTTAACATCGAACATATCAATTTATTAAGTAATAATCCAAGTAAATTT GAGGGATTAAAACAATATGGCATTGATATTGCAGAAAGAATTGAAGTTATCGTACCAGAAACGGTACAT AATCATGATTATATGGTAACGAAAAAAATAAAAATGGGTCATTTAATATAGGAGGACTTTAACATGAAT TTTGAAGGTAAATTAATTGGAAAAGATTTGAAAGTTGCAATCGTAGTTAGTCGATTTAATGATTTTATC ACTGGAAGATTACTTGAAGGTGCAAAAGATACTTTGATTCGACATGATGTTAATGAAGACAATATTGAT GTAGCATTTGTTCCTGGTGCGTTTGAAATTCCTTTAGTAGCTAAAAAATTAGCCTCATCAGGAAATTAT GATGCAATAATTACATTAGGATGCGTAATTCGCGGTGCTACGTCTCATTATGATTATGTTTGTAATGAA GTGCGAAAGGTGTTTCTAAAGTAAATGATCAAACTAATGTACCAGTCATATTTGGTATTTTAACGACTG AAAGTATTGAACAAGCTGTGGAAAGAGCAGGTACGAAAGCTGGTAATAAAGGTGCCGAAGCAGCAGTAA GTGCAATTGAAATGGCTAATTTATTAAAATCTATAAAAGCATAG

Claims: What is claimed is: 1 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2 2 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg the same mature polypeptide expressed by the nbA gene contamed in the Staphylococcus aureus of the deposited stram 3 An isolated polynucleotide compnsmg a polynucleotide encodmg a polypeptide compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 4 An isolated polynucleotide that is complementary to the polynucleotide of claim 1 5 The polynucleotide of Claim 1 wherem the polynucleotide is DNA or RNA 6 The polynucleotide of Claim 1 compnsmg the nucleic acid sequence set forth in SEQ ID NO l 7 The polynucleotide of Claim 1 compnsmg nucleotide 1 to the stop codon which begins at nucleotide numbei 1180 set forth m SEQ ID NO 1 8 The polynucleotide of Claim 1 which encodes a polypeptide compπsmg the ammo acid sequence of SEQ ID NO 2 9 A vector compnsmg the polynucleotide of Claim 1 10 A host cell compnsmg the vector of Claim 9 11 A process for producmg a polypeptide compnsmg expressmg from the host cell of Claim 10 a polypeptide encoded by said DNA 12 A process foi producmg a nbA polypeptide or fragment comprising cultuπng a host of claim 10 under conditions sufficient for the production of said polypeptide or fragment 13 A polypeptide compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 14 A polypeptide compnsmg an ammo acid sequence as set forth m SEQ ID NO 2 15 An antibody against the polypeptide of claim 14 16 An antagonist which inhibits the activity or expression of the polypeptide of claim 14 17 A method for the treatment of an mdividual m need of nbA polypeptide compπsmg admmistermg to the mdividual a therapeutically effective amount of the polypeptide of claim 14 18 A method for the treatment of an mdividual havmg need to inhibit nbA polypeptide compπsmg administering to the mdividual a therapeutically effective amount of the antagomst of Claim 14 19 A process for diagnosing a disease related to expression or activity of the polypeptide of claim 14 m an mdividual compnsmg (a) determinmg a nucleic acid sequence encodmg said polypeptide, and/or (b) analyzing for the presence or amount of said polypeptide m a sample denved from the mdividual 20 A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 14 compπsmg contactmg a composition compπsmg the polypeptide with the compound to be scieened undei conditions to permit mteraction between the compound and the polypeptide to assess the mteraction of a compound, such mteraction bemg associated with a second component capable of providing a detectable signal m response to the mteraction of the polypeptide with the compound. and determinmg whether the compound interacts with and activates or inhibits an activity of the polypeptide by detectmg the presence or absence of a signal generated from the mteraction of the compound with the polypeptide 21 A method for mducmg an unmunological response in a mammal which comprises inoculating the mammal with πbA polypeptide of claim 14. or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said animal from disease 22 A method of mducmg immunological response in a mammal which compnses delivering a nucleic acid vector to direct expression of nbA polypeptide of claim 14, or fragment or a vanant thereof, for expressmg said nbA polypeptide, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody and or T cell immune response to protect said animal from disease 23 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compπsmg the ammo acid sequence of SEQ ID NO 4 24 An isolated polynucleotide compnsmg a polvnucleotide having at least a 70% identity to the polynucleotide sequence of SEQ ID NO 3 or 7

Inventors: BLACK MICHAEL T, BURNHAM MARTIN K R, DEBOUCK CHRISTINE, FEDON JASON C, HODGSON JOHN E, JAWORSKI DEBORAH D, KNOWLES DAVID J C, LONETTO MICHAEL A, MOONEY JEFFREY, NICHOLAS RICHARD O, PALMER LESLIE M, PRATT JULIE M, REICHARD RAYMOND W, ROSENBERG MARTIN, TRAINI CHRISTOPHER M, WANG MIN, WARD JUDITH M, WARREN RICHARD L, ZHONG YIYI, BLACK, MICHAEL, T., BURNHAM, MARTIN, K., R., DEBOUCK, CHRISTINE, FEDON, JASON, C., HODGSON, JOHN, E., JAWORSKI, DEBORAH, D., KNOWLES, DAVID, J., C., LONETTO, MICHAEL, A., MOONEY, JEFFREY, NICHOLAS, RICHARD, O., PALMER, LESLIE, M., PRATT, JULIE, M., REICHARD, RAYMOND, W., ROSENBERG, MARTIN, TRAINI, CHRISTOPHER, M., WANG, MIN, WARD, JUDITH, M., WARREN, RICHARD, L., ZHONG, YIYI
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 1998
Main classification: A61K38
IPC codes: A61K31, A61K38, A61K39, A61K48, A61P1, A61P9, A61P11, A61P13, A61P17, A61P19, A61P25, A61P27, A61P43, C07H21, C07K14, C07K16, C12N1, C12N5, C12N9, C12N15, C12P21, C12R1, G01N33